Literature DB >> 349095

Antibacterial activity of cefamandole in vitro.

B R Meyers, S Z Hirschman.   

Abstract

Cefamandole, a new cephalosporin derivative, was found to have a broad spectrum of antimicrobial activity against a cross-section of both gram-positive and gram-negative bacteria isolated clinically. Gram-positive cocci, except for Streptococcus faecalis, were extremely susceptible to cefamandole; penicillin G-resistant Staphylococcus aureus also was highly susceptible. Minimal bactericidal concentrations for gram-positive cocci approximated the minimal inhibitory concentrations. Strains of Haemophilus influenzae were very susceptible to the drug. Most strains of Escherichia coli, Klebsiella species, and Proteus species were inhibited by low concentrations of cefamandole, Salmonella typhi, including ampicillin- and chloramphenicol-resistant strains, was inhibited by low concentrations of cefamandole. Susceptible bacteria became increasingly resistant as the inoculum size was increased. Strains of Pseudomonas were resistant to cefamandole.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 349095     DOI: 10.1093/infdis/137.supplement.s25

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

1.  Evaluation of the Cathra inoculating device for susceptibility testing of methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains.

Authors:  J M Boyce; M C Bonner; W R Lockwood
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

2.  Pharmacokinetics and safety of cefamandole in infants and children.

Authors:  C T Chang; A J Khan; M M Agbayani; R Jhaveri; I Amin; H E Evans
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

3.  Pharmacology, Safety, and efficacy of cefamandole in childhood infections.

Authors:  M C Thirumoorthi; A S Dajani; C V Vincent; M J Maurer
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

4.  Cefamandole therapy in anaerobic infections.

Authors:  R N Greenberg; M C Scalcini; C V Sanders; A C Lewis
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

5.  Pharmacokinetics and safety of cefamandole in newborn infants.

Authors:  M M Agbayani; A J Khan; P Kemawikasit; W Rosenfeld; D Salazar; K Kumar; L Glass; H E Evans
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

6.  [Perioperative cefamandole prevention in aortocoronary bypass operations: the course of serum levels in extracorporeal circulation].

Authors:  W Klepetko; A Georgopoulos; W Graninger; J Miholic; W Sandtner
Journal:  Langenbecks Arch Chir       Date:  1984
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.